The BCS, BDDCS, and regulatory guidances

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1774-1778

  Chen, Mei Ling ^a   Amidon, Gordon L ^b   Benet, Leslie Z ^c   Lennernas, Hans ^d   Yu, Lawrence X ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

BCS; BDDCS; biopharmaceutics classification system; biopharmaceutics drug disposition classification system; drug metabolism; drug permeability

Indexed keywords

METOPROLOL; SOTALOL;

BIOEQUIVALENCE; BIOPHARMACEUTICAL DRUG DISPOSITION CLASSIFICATION SYSTEM; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; COMPUTER SYSTEM; DRUG ABSORPTION; DRUG LEGISLATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; INFORMATION PROCESSING; NONHUMAN; NOTE; PRIORITY JOURNAL;

BIOPHARMACEUTICS; HUMANS; PERMEABILITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79959906965     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0438-1     Document Type: Note

References (19)

1. GL Amidon H Lennernäs VP Shah JR Crison 1995 A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 413 420 7617530 10.1023/A:1016212804288 1:CAS:528:DyaK2MXksVGqur8%3D
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000 August. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070246.pdf.
3. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on the Investigation of Bioequivalence. 2010 January 20. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2010/01/WC500070039.pdf.
4. CY Wu LZ Benet 2005 Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System Pharm Res 22 11 23 15771225 10.1007/s11095-004-9004-4 1:CAS:528:DC%2BD2MXhtlCks70%3D (Pubitemid 40558141)
5. LZ Benet GL Amidon DM Barends H Lennernäs JE Polli VP Shah SA Stavchansky LX Yu 2008 The use of BDDCS in classifying the permeability of marketed drugs Pharm Res 52 3 483 488 10.1007/s11095-007-9523-x
6. T Takagi C Ramachandran M Bermejo S Yamashita LX Yu GL Amidon 2006 A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain and Japan Mol Pharm 3 631 643 17140251 10.1021/mp0600182 1:CAS:528:DC%2BD28XhtVagsr%2FN (Pubitemid 46087480)
7. ML Chen L Yu 2009 The use of drug metabolism for prediction of intestinal permeability Mol Pharm 6 74 81 19132929 10.1021/mp8001864 1:CAS:528: DC%2BD1MXjt1GmtA%3D%3D
8. Y Yan PJ Faustino DA Volpe RC Lyon LX Yu 2007 Biopharmaceutics classification of selected beta-blockers: Solubility and permeability class membership Mol Pharm 4 608 614 10.1021/mp070028i (Pubitemid 47310172)
9. H Lennernäs 2007 Intestinal permeability and its relevance for absorption and elimination Xenobiotica 37 1015 1051 17968735 10.1080/00498250701704819 (Pubitemid 350035536)
10. H Lennernäs 1997 Human jejunal effective permeability and its correlation with preclinical drug absorption models J Pharm Pharmacol 49 627 638 9255703 10.1111/j.2042-7158.1997.tb06084.x (Pubitemid 27341705)
11. A Dahan JM Miller JM Hilfinger S Yamashita LX Yu H Lennernäs GL Amidon 2010 High-permeability criterion for BCS classification: Segmental/pH dependent permeability consideration Mol Pharm 7 1827 1834 10.1021/mp100175a 1:CAS:528:DC%2BC3cXhtFSnsbrJ
12. P Artursson K Palm K Luthman 2001 Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv Drug Deliv Rev 46 27 43 11259831 10.1016/S0169-409X(00)00128-9 1:CAS:528:DC%2BD3MXitVOhs7s%3D
13. A Khandelwal PM Bahadduri C Chang JE Polli PW Swaan S Ekins 2007 Computational models to assign biopharmaceutics drug disposition classification from molecular structure Pharm Res 24 2249 2262 17846869 10.1007/s11095-007- 9435-9 1:CAS:528:DC%2BD2sXht1Krt77N (Pubitemid 350064250)
14. TI Oprea A Tropsha J-L Faulon MD Rintoul 2007 Systems chemical biology Nat Chem Biol 3 447 450 17637771 10.1038/nchembio0807-447 1:CAS:528: DC%2BD2sXnvFaqs7Y%3D (Pubitemid 47080379)
15. TI Oprea EE May A Leitão A Tropsha 2011 Computational systems chemical biology Meth Mol Biol 672 459 488 10.1007/978-1-60761-839-3-18 1:CAS:528:DC%2BC3cXhtlejsr%2FP
16. H Lennernäs B Abrahamsson 2005 The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J Pharm Pharmacol 57 273 285 15807982 10.1211/0022357055263 (Pubitemid 40326200)
17. HH Blume BS Schug 1999 The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver? Eur J Pharm Sci 9 117 121 10620723 10.1016/S0928-0987(99)00076-7 1:CAS:528:DC%2BD3cXhtVeqtQ%3D%3D (Pubitemid 30012067)
18. LX Yu GL Amidon JE Polli H Zhao MU Mehta DP Conner VP Shah LP Lesko M-L Chen VHL Lee AS Hussain 2002 Biopharmaceutics Classification System: The scientific basis for biowaiver extensions Pharm Res 19 7 921 925 12180542 10.1023/A:1016473601633 1:CAS:528:DC%2BD38Xltl2is7g%3D (Pubitemid 34804232)
19. M Yazdanian K Briggs C Jankovsky A Hawi 2004 The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs Pharm Res 21 293 299 15032311 10.1023/B:PHAM.0000016242.48642.71 1:CAS:528:DC%2BD2cXhtlWqtrc%3D (Pubitemid 38221975)